Difference between revisions of "Electrodesiccation and curettage"
Jump to navigation
Jump to search
(nl update 1) |
|||
(10 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
'''Electrodesiccation and curettage''', abbreviated '''EDC''', is a procedure in which: | '''Electrodesiccation and curettage''', abbreviated '''EDC''' and '''E+C''', is a procedure in which: | ||
# The lesion is cut-off. | # The lesion is cut-off (sent to pathology). | ||
# The surgical site is cauterized using electricity (electrodesiccation). | # The surgical site is cauterized using electricity (electrodesiccation). | ||
# The electrodesiccated tissue is scrapped off (curettage). | # The electrodesiccated tissue is scrapped off (curettage). | ||
==General== | |||
*EDCs are typically done by family physicians and dermatologists for non-[[melanoma]] skin cancers.<ref name=pmid12170889>{{Cite journal | last1 = Goldman | first1 = G. | title = The current status of curettage and electrodesiccation. | journal = Dermatol Clin | volume = 20 | issue = 3 | pages = 569-78, ix | month = Jul | year = 2002 | doi = | PMID = 12170889 }}</ref> | |||
*The practise is not without controversy.<ref name=pmid12170889/><ref name=pmid20677531>{{Cite journal | last1 = Reschly | first1 = MJ. | last2 = Shenefelt | first2 = PD. | title = Controversies in skin surgery: electrodessication and curettage versus excision for low-risk, small, well-differentiated squamous cell carcinomas. | journal = J Drugs Dermatol | volume = 9 | issue = 7 | pages = 773-6 | month = Jul | year = 2010 | doi = | PMID = 20677531 }}</ref> | |||
Limitations of the technique are: | |||
*The [[margin status]] is assessed clinically. | |||
**The [[pathologist]] cannot comment on whether the margin is clear or the [[surgical clearance]]. | |||
*The size of the lesion is usually impossible to determine on pathology. | |||
==Sign out== | |||
<pre> | |||
Skin, Right Shoulder, Biopsy with Curettage and Electrodesiccation (CED): | |||
- BASAL CELL CARCINOMA, margin status assessed clinically during CED. | |||
</pre> | |||
<pre> | |||
Right Upper Lip, Biopsy with Curettage and Electrodesiccation (C+E): | |||
- INVASIVE SQUAMOUS CELL CARCINOMA (well-differentiated), margin status assessed clinically during C+E. | |||
</pre> | |||
<pre> | |||
Skin Lesion, Right Midline Back, Curettage and Electrodesiccation (C&E): | |||
- BASAL CELL CARCINOMA, margin status assessed clinically during C&E. | |||
</pre> | |||
==References== | |||
{{Reflist|1}} | |||
[[Category:Dermatopathology]] | [[Category:Dermatopathology]] |
Latest revision as of 16:35, 20 December 2023
Electrodesiccation and curettage, abbreviated EDC and E+C, is a procedure in which:
- The lesion is cut-off (sent to pathology).
- The surgical site is cauterized using electricity (electrodesiccation).
- The electrodesiccated tissue is scrapped off (curettage).
General
- EDCs are typically done by family physicians and dermatologists for non-melanoma skin cancers.[1]
- The practise is not without controversy.[1][2]
Limitations of the technique are:
- The margin status is assessed clinically.
- The pathologist cannot comment on whether the margin is clear or the surgical clearance.
- The size of the lesion is usually impossible to determine on pathology.
Sign out
Skin, Right Shoulder, Biopsy with Curettage and Electrodesiccation (CED): - BASAL CELL CARCINOMA, margin status assessed clinically during CED.
Right Upper Lip, Biopsy with Curettage and Electrodesiccation (C+E): - INVASIVE SQUAMOUS CELL CARCINOMA (well-differentiated), margin status assessed clinically during C+E.
Skin Lesion, Right Midline Back, Curettage and Electrodesiccation (C&E): - BASAL CELL CARCINOMA, margin status assessed clinically during C&E.
References
- ↑ 1.0 1.1 Goldman, G. (Jul 2002). "The current status of curettage and electrodesiccation.". Dermatol Clin 20 (3): 569-78, ix. PMID 12170889.
- ↑ Reschly, MJ.; Shenefelt, PD. (Jul 2010). "Controversies in skin surgery: electrodessication and curettage versus excision for low-risk, small, well-differentiated squamous cell carcinomas.". J Drugs Dermatol 9 (7): 773-6. PMID 20677531.